One of the aforementioned found hits, acting as a μOR antagonist, was later found to be a novel scaffold κ-opioid receptor (κOR) antagonist and was evaluated in in vitro, in vivo and in silico experiments [88] as κOR antagonists act as promising new treatments for certain mood disorders [89]. Here, OPRK1 is linked to mood disorder.